Skip to main content
TIBET AIM PHARM. INC. logo

TIBET AIM PHARM. INC. — Investor Relations & Filings

Ticker · 002826 ISIN · CNE100002C39 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,085 across all filing types
Latest filing 2022-01-17 Director's Dealing
Country CN China
Listing Shenzhen Stock Exchange 002826

About TIBET AIM PHARM. INC.

https://www.emyy.cn

Tibet Aim Pharm. Inc. is a pharmaceutical enterprise focused on the research, development, production, and distribution of medicinal products. The company integrates traditional Tibetan medicine with modern pharmaceutical manufacturing processes to develop a diverse portfolio of treatments. Its core product range typically includes cardiovascular medications, digestive system therapies, and specialized herbal formulations derived from high-altitude botanical sources. Tibet Aim Pharm. Inc. emphasizes the modernization of traditional formulas through rigorous clinical testing and standardized production techniques. The company serves healthcare providers and patients by providing therapeutic solutions that bridge ancient medical knowledge with contemporary scientific standards.

Recent filings

Filing Released Lang Actions
关于董事减持计划实施完成的公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding the completion of a share reduction plan by a company director, 彭辉. It details the number of shares reduced, dates, prices, and the impact on shareholding percentages. It also references compliance with securities laws and regulations. There is no financial report, earnings data, or management discussion. The content fits the definition of a Director's Dealing report, which covers personal share transactions by company directors and executives.
2022-01-17 Chinese
关于大股东、董事减持计划实施完成的公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding the completion of a shareholding reduction plan by a major shareholder and director, 周战. It details the shareholding before and after the reduction, confirms compliance with relevant securities laws and regulations, and states that the reduction plan has been fully implemented. There is no financial report, earnings data, or management discussion. The content fits the category of a Major Shareholding Notification, as it concerns changes in significant share ownership levels and disclosure of such changes.
2022-01-17 Chinese
关于大股东部分股份解除质押的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from a company regarding the release of a portion of shares pledged by a major shareholder. It details the shareholder's name, number of shares released from pledge, pledge dates, and related information. There is no financial statement, earnings data, or management discussion. The document is short (1476 characters) and focuses on share pledge status, which is a capital structure related update. This fits the category of Capital/Financing Update (CAP).
2022-01-14 Chinese
关于募集资金使用完毕及募集资金账户注销完成的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the completion of the use of raised funds and the closure of the related fundraising accounts by the company. It details the amount of funds raised, their management, usage, and the formal closure of the accounts. There is no presentation of financial statements or comprehensive financial performance data. The document is relatively short (2170 characters) and serves as a formal notification about the fundraising completion and account closure, not a full financial report or audit. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes.
2021-12-31 Chinese
关于子公司蒙脱石原料药通过CDE技术审评的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company regarding its subsidiary's pharmaceutical product passing a technical review by the CDE (Center for Drug Evaluation). It provides details about the registration, approval status, and potential impact on the company. The document is short (939 characters) and does not contain financial data, earnings, or detailed report content. It is an announcement of a regulatory approval event rather than a financial report or management discussion. It does not fit categories like Annual Report, Earnings Release, or Management Reports. It is a regulatory announcement about a product approval, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2021-12-14 Chinese
2021年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 2021 second extraordinary shareholders' meeting of the company. It details the meeting's convening, attendance, voting results, and legal opinions confirming the validity of the meeting and its resolutions. There is no financial data or detailed report content, only the official voting results and procedural information. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short (2023 characters), consistent with an announcement rather than a full report.
2021-12-03 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.